| Autor: |
Draznin, Julia, Sun, Weijing |
| Předmět: |
|
| Zdroj: |
Update on Cancer Therapeutics; Sep2006, Vol. 1 Issue 3, p353-365, 13p |
| Abstrakt: |
Abstract: Cancer of the large bowel (colorectal cancer (CRC)) is one of the most common gastrointestinal tract malignancies, especially in North America and Europe. In the past several years, tremendous advances have been achieved in the treatment of the disease in both metastatic and adjuvant settings with developments of new cytotoxic (e.g. oxaliplatin, irinotecan, capecitabine) and novel molecular oriented agents (e.g. bevacizumab, cetuximab). These improvements have not only changed the survival statistics and prospect of the disease, but also the quality of life of these patients. The surgical intervention and local therapies remain the mainstay of the treatment of patients with hepatocellular carcinoma (HCC), the third leading cause of death due to cancer worldwide. However, tremendous efforts are in process to promote better outcome with systemic treatment via utilization of chemotherapy and novel biological agents. Carcinoma of the pancreas and biliary track (cholangiocarcinoma) continues to present an enormous diagnostic and therapeutic challenge. Evidence supports the multidisciplinary treatment with pre- or post-operative chemotherapy and chemoradiation for locally advanced disease. Results of combining cytotoxic and biologic/target oriented agents in the treatment of metastatic disease are encouraging. [Copyright &y& Elsevier] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full Text from ScienceDirect